Dataset Information

¹¹C-radiolabeled aptamer for imaging of tumors and metastases using positron emission tomography- computed tomography.

ABSTRACT: Identification of primary tumors and metastasis sites is an essential step in cancer diagnostics and the following treatment. Positron emission tomography-computed tomography (PET/CT) is one of the most reliable methods for scanning the whole organism for malignancies. In this work, we synthesized an ¹¹C-labeled oligonucleotide primer and hybridized it to an anti-cancer DNA aptamer. The ¹¹C-aptamer was applied for in vivo imaging of Ehrlich ascites carcinoma and its metastases in mice using PET/CT. The imaging experiments with the ¹¹C-aptamer determined very small primary and secondary tumors of 3 mm² and less. We also compared ¹¹C imaging with the standard radiotracer, 2-deoxy-2-[fluorine-18]fluoro-D-glucose (¹⁸F-FDG), and found better selectivity of the ¹¹C-aptamer to metastatic lesions in the metabolically active organs than ¹⁸F-FDG. ¹¹C radionuclide with an ultra-short (20.38 min) half-life is considered safest for PET/CT imaging and does not cause false-positive results in heart imaging. Its combination with aptamers gives us high-specificity and high-contrast imaging of cancer cells and can be applied for PET/CT-guided drug delivery in cancer therapies.

SUBMITTER: Ozerskaya AV

PROVIDER: S-EPMC8601970 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

11C-radiolabeled aptamer for imaging of tumors and metastases using positron emission tomography- computed tomography.

Ozerskaya Anastasia V AV Zamay Tatiana N TN Kolovskaya Olga S OS Tokarev Nikolay A NA Belugin Kirill V KV Chanchikova Natalia G NG Badmaev Oleg N ON Zamay Galina S GS Shchugoreva Irina A IA Moryachkov Roman V RV Zabluda Vladimir N VN Khorzhevskii Vladimir A VA Shepelevich Nikolay N Gappoev Stanislav V SV Karlova Elena A EA Saveleva Anastasia S AS Volzhentsev Alexander A AA Blagodatova Anna N AN Lukyanenko Kirill A KA Veprintsev Dmitry V DV Smolyarova Tatyana E TE Tomilin Felix N FN Zamay Sergey S SS Silnikov Vladimir N VN Berezovski Maxim V MV Kichkailo Anna S AS

Molecular therapy. Nucleic acids 20211021

Identification of primary tumors and metastasis sites is an essential step in cancer diagnostics and the following treatment. Positron emission tomography-computed tomography (PET/CT) is one of the most reliable methods for scanning the whole organism for malignancies. In this work, we synthesized an 11C-labeled oligonucleotide primer and hybridized it to an anti-cancer DNA aptamer. The 11C-aptamer was applied for in vivo imaging of Ehrlich ascites carcinoma and its ...[more]

PMID: 34853715

Similar Datasets

Project description:ObjectivesComputed tomography (CT) can perform comprehensive cardiac imaging. We compared CT coronary angiography (CTCA) and CT myocardial perfusion (CTP) with 15O-water positron emission tomography (PET) and invasive coronary angiography (ICA) with fractional flow reserve (FFR).Methods51 patients (63 (61-65) years, 80 % male) with known/suspected coronary artery disease (CAD) underwent 320-multidetector CTCA followed by "snapshot" adenosine stress CTP. Of these 22 underwent PET and 47 ICA/FFR. Obstructive CAD was defined as CTCA stenosis >50 % and CTP hypoperfusion, ICA stenosis >70 % or FFR <0.80.ResultsPET hyperaemic myocardial blood flow (MBF) was lower in obstructive than non-obstructive territories defined by ICA/FFR (1.76 (1.32-2.20) vs 3.11 (2.44-3.79) mL/(g/min), P < 0.001) and CTCA/CTP (1.76 (1.32-2.20) vs 3.12 (2.44-3.79) mL/(g/min), P < 0.001). Baseline and hyperaemic CT attenuation density was lower in obstructive than non-obstructive territories (73 (71-76) vs 86 (84-88) HU, P < 0.001 and 101 (96-106) vs 111 (107-114) HU, P 0.001). PET hyperaemic MBF corrected for rate pressure product correlated with CT attenuation density (r = 0.579, P < 0.001). There was excellent per-patient sensitivity (96 %), specificity (85 %), negative predictive value (90 %) and positive predictive value (94 %) for CTCA/CTP vs ICA/FFR.ConclusionCT myocardial attenuation density correlates with 15O-water PET MBF. CTCA and CTP can accurately identify obstructive CAD.Key points•CT myocardial perfusion can aid the assessment of suspected coronary artery disease. • CT attenuation density from "snapshot" imaging is a marker of myocardial perfusion. • CT myocardial attenuation density correlates with 15 O-water PET myocardial blood flow. • CT attenuation density is lower in obstructive territories defined by invasive angiography. • Diagnostic accuracy of CTCA+CTP is comparable to invasive angiography + fractional flow reserve.

Project description:BackgroundCurrent imaging techniques may not detect all prostate cancer (PCa) lesions.ObjectiveTo evaluate positron emission tomography (PET)/computed tomography (CT) using the radiolabeled GRPR antagonist probe BAY86-7548 (68Ga-RM2) for localization of newly diagnosed PCa in comparison with multiparametric magnetic resonance imaging (mpMRI), histopathology, and immunohistochemistry (IHC).Design, setting, and participantsThis was a prospective study of 16 men with biopsy-proven PCa (2 low, 8 intermediate, and 6 high risk). 68Ga-RM2 PET/CT was performed within 4 wk after mpMRI and within 2 wk before radical prostatectomy and extended bilateral pelvic lymph node dissection.Outcome measurements and statistical analysisThe presence of cancer was evaluated by blinded specialists using a 5-point Likert scale, with lesions scoring 4 or 5 considered positive, on 68Ga-RM2 PET/CT, mpMRI, and 68Ga-RM2 PET/CT-mpMRI fused images for each of 12 anatomic areas of the prostate. Whole-mount, step-section pathology served as the reference standard. Expression of GRPR and prostate-specific membrane antigen (PSMA) was analyzed via IHC of tumor paraffin sections.Results and limitationsOf 192 areas analyzed, 128 contained cancer. The sensitivity, specificity, and accuracy of 68Ga-RM2 PET/CT imaging and mpMRI did not differ significantly; fusing the images maximized the sensitivity and accuracy (85.2% and 83.9%, respectively) and averaged the specificity (81.3%). The area under the receiver operating characteristic curve was 0.76 for PET visual analysis, 0.72 for PET quantitative analysis, 0.76 for mpMRI, and 0.85 for combined PET/CT and mpMRI analysis. 68Ga-RM2 uptake did not correlate with Gleason score. IHC analysis revealed weaker staining for GRPR than for PSMA, and the expression of these markers was not correlated (r=0.3882). The major limitation is the small sample size.Conclusions68Ga-RM2 PET/CT is promising for detection and localization of primary PCa, and complements mpMRI. GRPR expression appears to be independent from PSMA expression, suggesting that GRPR- and PSMA-targeted PET imaging may be complementary.Patient summaryThis pilot prospective study shows that a positron emission tomography probe that binds to a marker of prostate cancer, GRPR, improves the ability of magnetic resonance imaging to detect prostate cancer.

Dataset Information

¹¹C-radiolabeled aptamer for imaging of tumors and metastases using positron emission tomography- computed tomography.

Publications

<sup>11</sup>C-radiolabeled aptamer for imaging of tumors and metastases using positron emission tomography- computed tomography.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets